Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7311-7317

  Kim, Young Hak ^a,b   Ishii, Genichiro ^a   Goto, Koichi ^b   Nagai, Kanji ^b   Tsuta, Koji ^a   Shiono, Satoshi ^a,b   Nitadori, Junichi ^a,b   Kodama, Testuro ^c   Nishiwaki, Yutaka ^b   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CIGARETTE SMOKING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG PAPILLARY ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; PAPILLARY CARCINOMA; PLEURA CANCER; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 8444240380     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0811     Document Type: Article

References (36)

1. Spiro SG, Porter JC. Lung cancer-where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002;166:1166-96.
2. Pass HI, Mitchell JB, Johnson DH, et al. Lung cancer: principles and practice, 2nd edition. Philadelphia, Lippincott Williams & Wilkins; 2000.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
4. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
6. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
7. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
8. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41(Suppl 1):S29-42.
9. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
10. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993;68:162-5.
11. Volm M, Mattern J, Koomagi R. Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas. Clin Exp Metastasis 1998;16:595-602.
12. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7(Suppl 4): 31-9.
13. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
14. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
15. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
16. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
17. Argiris A, Mittal N, Masters G; Northwestern University, Chicago, IL; Evanston Northwestern Healthcare, Evanston, IL. Gefitinib (ZD1839) as first-line, compassionate use therapy in patients (pts) with advanced non-small-cell lung cancer (NSCLC), abstract 2729. Available at http://www.asco.org. Proc Am Soc Clin Oncol 2003;22:679
18. Ohar JA, Waller KS, DeMello D, et al. Administration of chronic intravenous platelet-activating factor induces pulmonary arterial atrophy and hypertension in rabbits. Lab Investig 1991;65:451-8.
19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumours with contributions by Pathologists from 14 Countries Series: WHO. World Health Organization. International Histological Classification of Tumours, 3rd edition. 1999, pp. 156.
20. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors, fifth edition. New York: John Wiley and Sons, Inc.; 1997.
21. Araki K, Ishii G, Yokose T, et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40:173-80.
22. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur. J Cancer 2004;40:56-63.
23. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
25. Howard L, West WAF, Gumerlock, Pet al. zd1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): a preliminary report of SWOG S0126, abstract O-187. 10th World Conference on Lung Cancer, August 10-14, 2003, Vancouver, British Columbia, Canada. Aurora, Colorado: International Association for the Study of Lung Cancer; 2003.
26. Suzuki T, Nakagawa T, Endo H, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003;42:35-41.
27. Moasser MM, Basso A, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
28. Anderson NG, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001;94:774-82.
29. Cappuzzo F, Gregore V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-63.
30. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60.
31. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash DC) 2004;304:1497-500.
32. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
33. Silver SA, Askin FB. True papillary carcinoma of the lung: a distinct clinicopathologic entity. Am J Surg Pathol 1997;21:43-51.
34. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002;26:358-64.
35. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-9.
36. Wu YL, Yang XN, Gu LJ, et al. The characteristics of patients with non-small cell lung cancer with complete response treated with ZD1839, abstract 2770. Available at http://www.asco.org. Proc Am Soc Clin Oncol 2003;22:689.